Management of chronic daily headache in children and adolescents

Pediatric Drugs

Volumn 10, Issue 1, 2008, Pages 23-29

  Mack, Kenneth J ^a   Gladstein, Jack ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Amitriptyline, therapeutic use; Analgesics, therapeutic use; Children; Corticosteroids, therapeutic use; Cyproheptadine, therapeutic use; Dihydroergotamine mesilate, therapeutic use; Flunarizine, therapeutic use; Gabapentin, therapeutic use

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYPROHEPTADINE; DECONGESTIVE AGENT; DIHYDROERGOTAMINE MESILATE; ERGOTAMINE; FLUNARIZINE; FLUOXETINE; GABAPENTIN; INDOMETACIN; ISOMETHEPTENE; METOCLOPRAMIDE; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROPRANOLOL; RIBOFLAVIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VERAPAMIL;

ANXIETY DISORDER; ASTHMA; AUTONOMIC DYSFUNCTION; BEDTIME DOSAGE; COMORBIDITY; CONDUCT DISORDER; CONSTIPATION; DEPRESSION; DIAGNOSTIC PROCEDURE; DIPLOPIA; DISABILITY; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPILEPSY; ERGOTISM; EXERCISE; EYE PAIN; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEMICRANIA CONTINUA; HUMAN; INTRACRANIAL HYPERTENSION; IRRITABILITY; KIDNEY FAILURE; LEARNING DISORDER; LOW DRUG DOSE; MIGRAINE; MOOD DISORDER; NEUROIMAGING; NIGHTMARE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC CHANGE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH IRRITATION; TACHYCARDIA; TERATOGENESIS; TINNITUS; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; CHILD; HEADACHE DISORDERS; HUMANS; TREATMENT OUTCOME;

EID: 37549042791     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810010-00003     Document Type: Review

References (37)

1. International Headache Society. International classification of headache disorders (ICHD-II). Cephalalgia 2004; 24 (Suppl. 1) 23-136
2. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology 2006; 66: 193-7
3. Kavuk I, Yavuz A, Cetindere U, et al. Epidemiology of chronic daily headache. Eur J Med Res 2003; 8: 236-40
4. Gladstein J, Holden EW, Peralta L, et al. Diagnoses and symptom patterns in children presenting to a pediatric headache clinic. Headache 1993; 33: 497-500
5. Hershey AD, Powers SW, Bentti AL, et al. Characterization of chronic daily headaches in children in a multidisciplinary headache center. Neurology 2001; 56: 1032-7
6. Silberstein SD, Lipton RB, Solomon S, et al. Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache 1994; 34: 1-7
7. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47: 871-5
8. Mack KJ. What incites new daily persistent headache in children? Pediatr Neurol 2004; 1: 122-5
9. Gladstein J, Holden EW. Chronic daily headache in children and adolescents: a 2-year prospective study. Headache 1996; 36: 349-51
10. Koenig MA, Gladstein J, McCarter RJ, et al. Pediatric Committee of the American Headache Society. Chronic daily headache in children and adolescents presenting to tertiary headache clinics. Headache 2002 Jun; 42 (6): 491-500
11. Howard L, Wessely S, Leese M, et al. Are investigations anxiolytic or anxiogenic? A randomized controlled trial of neuroimaging to provide reassurance in chronic daily headace. J Neurol Neurosurg Psychiatry 2005; 76 (11): 1558-64
12. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994; 44: 1353-4
13. Schwedt TJ, Guo Y, Rothner AD. "Benign" imaging abnormalities in children and adolescents with headache. Headache 2006; 46: 387-98
14. Hershey AD, Powers SW, Vockell AL, et al. PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology 2001; 57: 2034-9
15. Mathew NT, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache 1990; 30: 634-8
16. Maizels M, Burchette R. Somatic symptoms in headache patients: the influence of headache diagnosis, frequency, and co morbidity. Headache 2004; 44: 983-93
17. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc 2007; 82 (3): 308-13
18. Silberstein SD, Liu D. Drug overuse and rebound headache. Curr Pain Headache Rep 2002; 6: 240-7
19. Relja G, Granato A, Bratina A, et al. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia 2006 May; 26 (5): 589-95
20. Raskin NH. Repetitive intravenous ergotamine therapy for the treatment of intractable migraine. Neurology 1986; 36: 995-7
21. Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 2000; 40: 720-3
22. Krymchantowski AV, Barbosa JS. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. Arq Neuropsiquiatr 2001; 59: 708-11
23. Lewis D, Ashwal S, Hershey A, et al. American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63: 2215-24
24. Linde K, Rossnagel K. Propanolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; 2: CD003225
25. Swanson JW. Topiramate for migraine prevention. Curr Neurol Neurosci Rep 2005; 5: 77-8
26. Borzy JC, Koch TK, Schimschock JR. Effectiveness of topimarate in the treatment of pediatric chronic daily headache. Pediatr Neurol 2005; 33 (5): 314-6
27. Comer SD, Haney M, Fischman MW, et al. Cyproheptadine produced modest increases in total caloric intake by humans. Physiol Behav 1997; 62: 831-9
28. Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches:the role of antidepressants. Neurol Sci 2004; 25 Suppl. 3: S171-5
29. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; 3: CD003226
30. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997; 20: 427-51
31. Gherpelli JL, Esposito SB. A prospective randomized double blind placebo controlled crossover study of fluoxetine efficacy in the prophylaxis of chronic daily headache in children and adolescents. Arq Neuropsiquiatr 2005; 63: 559-63
32. Adelman LC, Adelman JU, VonSeggern R, et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000; 40: 572-80
33. Bianchi A, Salomone S, Caraci F, et al. Role of magnesium, coenzymeQ10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm 2004; 69: 297-312
34. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45: 315-24
35. Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002; 27: 163-81
36. Hershey AD, Powers SW, Bentti AL, et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache 2000; 40: 539-49
37. Galli F, Patron L, Russo PM, et al. Chronic daily headache in childhood and adolescence: clinical aspects and a 4-year follow-up. Cephalalgia 2004; 24: 850-8